Transcranial Direct Current Stimulation and Chronic Pain
Unknown statusNot applicableNCT05863494
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This clinical trial uses transcranial direct current stimulation (tDCS) using the patented tKIWI system to safely reduce self-reported chronic pain with little to no side effects to improve our understanding and ability to accurately diagnose pain disorders which would facilitate the development of pharmacologic and non-pharmacologic treatment modalities using deep learning architecture built into the tKIWI.
Study details
- Official title
- Toward Personalized Treatment of Chronic Pain Using Transcranial Direct Current Stimulation Paired With Deep Learning
- Conditions
- Interventions
- Device: Transcranial Direct Current Stimulation (tDCS)
- Device: Transcranial Direct Current Stimulation (tDCS) sham
- Sponsor
- University of Arizona
- Collaborators
- ni20
- Start date
- 2023-06-01
- Primary completion
- 2023-07
- Sex
- All
- Age range
- from 18 Years to 79 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age: 18-79 years old * Gender: Any * Ethnicity: Any * Chronic pain (\> 3-months); No current use of nonprescription opioids (\< 1 month); Able and willing to comply with scheduled visits and other study-related procedures to complete the study; Willing and able to give informed consent. Exclusion Criteria: * Diagnosis (as defined by DSM-IV) of: any psychotic disorder (lifetime); eating disorder (current or within the past year); obsessive compulsive disorder (lifetime)); mental retardation. * History of drug or alcohol abuse or dependence (as per DSM-IV criteria) within the last 3 months (except nicotine and caffeine). * Subject is on regular benzodiazepine medication which it is not clinically appropriate to discontinue. * Subject requires a rapid clinical response due to inanition, psychosis or high suicide risk. * Neurological disorder or insult, e.g., recent stroke (CVA), which places subject at risk of seizure or neuronal damage with tDCS. * Subject has metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites. * Female subject who is pregnant. * Participants who are not fluent in English will not be included in the trial for safety reasons: a) It is usually not possible to have an interpreter reliably available every weekday for up to 4 weeks and it is not safe to give tDCS to a subject who cannot tell us immediately of any side effects; Note that translation of the proposed ACT activity into English has not been validated and that we cannot be confident that they would be accurately translated and validated. * Minors * Older than 79 years old * last use \>24 months * history of EEG or any electrical implant (i.e. pacemaker) * history of Parkinson's, diagnosis of bipolar, schizophrenia/schizo-affective d/o, OCD, epilepsy, alzheimers * taking antipsychotic drugs
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05863494